adjust model ahead interim
follow interim data updat mirati clinical-stag kra inhibitor
competitor updat model lower target price
reiter outperform rate lower market
share assumpt sitravatinib combo remain posit
program take conserv view await interim data
provid potenti upsid use conserv estim
adjust estim light recent posit updat amgen
kra inhibitor believ month ahead
see potenti first-mov captur signific share given high unmet need
estim peak penetr appli po reflect later entri
market establish experienc competitor continu expect launch
gener peak unadjust sale initi data expect
earli octob could drive substanti upsid estim valuat
sitravatinib combo potenti revis estim revis
estim sitravatinib nsclc bladder rcc reflect revis market
assumpt continu expect sitravatinib nsclc launch
anticip usag combin gener ww
unadjust peak sale assum peak penetr nsclc
bladder neo-adjuv rcc po
valuat tp base sum part dcf analysi discount cash
flow use wacc appli termin valu growth rate chang
expect ep due chang market assumpt
catalyst look next expect interim data possibl aacr-
yet confirm locat interim updat note mirati schedul
present tripl meet next month
risk tp rate clinic development commerci market
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
mirati clinical-stag biotechnolog compani dedic
advanc novel therapeut extend live patient directli
address genet immunolog driver cancer
blue sky scenario valu per share reflect po
sitravatinib
grey sky scenario valu per share reflect po
sitravatinib nsclc po bladder rcc
 close
focu kra
kra solid tumor repres unaddress market opportun
aim target yet see proof-of-concept clinic
data preclin data promis cdx pancreat pdx lung
model tumor recur despit stop treatment vivo anti-
tumor activ target preval kra mutat
occur nsclc adenocarcinoma patient colorect cancer
patient pancreat patient compani estim
address patient zehir et al cheng et al compani
expect month behind see
potenti meaning upsid initi data differenti
clinic stage kra candid month ahead clinic
trial figur month present updat data nsclc
wclc achiev orr diseas control rate dose
nsclc believ greater access resourc
development/commerci expertis might allow widen lead given
current absenc data likelihood launch ahead
address much unmet need assum peak penetr
appli probabl success po phase interim
data expect possibl mirati present aacr-nci-eortc
meet abstract present differenti efficaci safeti
durat could drive meaning conserv assumpt
figur kra asset develop
upcom kra program follow preclin success mirati
continu lay groundwork anoth kra inhibitor note
incorpor model preclin data trial design announc
time compar compani estim address kra market market
kra
figur kra program direct inhibitor kra
focu sitravatinib
focus sitravatinib combo sitravatinib tyrosin kinas
receptor inhibitor target famili receptor mer split
famili receptor kit sitravatinib current evalu singl
agent combin opdivo nivolumab sitravatinib combin
trial on-going non-smal cell lung cancer nsclc ph bladder cancer ph
renal cell carcinoma rcc ph monotherapi trial underway nsclc
ph melanoma ph see limit potenti monotherapi due
larg number commerci avail multi-target kinas inhibitor
figur interim data sitravatinib combo refractori nsclc
opportun nsclc docetaxel could prove tough compar
believ primari commerci opportun combin use
nsclc current phase interim phase data sitravatinib opdivo
checkpoint refractori nsclc show patient clinic benefit
sd/pr/cr patient tumor regress patient
confirm complet partial respons preliminari median kaplan-
meier estim durat respons month howev docetaxel could prove
stronger compar expect random clinic trial
treatment nsclc docetaxel shown orr aguiar jr et al
manag estim orr sitravatinib opdivo docetaxel exhibit
orr higher end histor rang orr lower manag
expect sitravatinib combo may show statistically-improv orr
interim analysi could delay submiss pend full overal surviv data
result downward pressur share
indicationcatalyststimingnsclcinterim analysi orr acceler approv hnscciniti phase data mechan nsclc initi phase proof initi phase proof rcc initi phase proof ovarian initi phase proof gastric initi phase proof demonstr clinic achiev confirm partial complet responseinterim phase efficaci data checkpont refractori nsclc median dor month median month median os month charl martineau pm univers toronto septemb
model ww peak unadjust revenu sitravatinib nsclc
compris major like sitravatinib opportun forecast us unadjust
peak sale nsclc bladder rcc ex-u
estim peak unadjust sale anticip us launch
nsclc po bladder po rcc neoadjuv
po label expans earlier line use addit indic could
provid upsid forecast
valu mirati use sum part discount cash flow analysi arriv
tp valuat impact recent market condit trade
transact multipl discount cash flow use wacc roughli line
pre-revenu smid-cap biotech peer forecast cash flow account
known expect product launch patent expir competit threat
beyond forecast appli termin growth rate cash flow account
possibl patent expiri sitravatinib expect patent
protect persist beyond date
fiscal year end million except per share opex tax stock base increas /decreas capit free charl martineau pm univers toronto
figur valuat million except per share
dilut share current
risk target price rate
clinic development valuat share upsid potenti
base outcom clinic trial sitravatinib
pipelin asset shown clinic ineffect unsaf would expect
neg pressur share
regulatori food drug administr fda european medicin agenc
ema regulatori bodi approv requir mirati market
sell therapeut delay outright reject approv
investig asset could neg impact futur cash flow
valu mirati share furthermor fda ema could revok market
author market product due safeti efficaci concern
commerci sale wors consensu expect could
see neg impact share
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
